For the treatment of breast cancer, preclinical studies are ongoing to examine the effects of CAR-T cell therapy on various tumor specific antigens including mucin 1 (MUC1), HER2, Lewis Y, mesothelin, and folate receptor alpha (FR-α) (119). This evidence concerns the gene ERBB2 and breast cancer.